相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Transarterial chemoembolisation enhances programmed death-1 and programmed death-ligand 1 expression in hepatocellular carcinoma
Ahmed Montasser et al.
HISTOPATHOLOGY (2021)
Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma
Josep M. Llovet et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2021)
Changes in the Peripheral Blood Treg Cell Proportion in Hepatocellular Carcinoma Patients After Transarterial Chemoembolization With Microparticles
Zhizhong Ren et al.
FRONTIERS IN IMMUNOLOGY (2021)
Understanding LAG-3 Signaling
Luisa Chocarro et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Effects of transarterial chemoembolization on the immunological function of patients with hepatocellular carcinoma
Jingjing Guo et al.
ONCOLOGY LETTERS (2021)
Development of a Prognostic Scoring System for Hepatocellular Carcinoma Patients With Main Portal Vein Tumor Thrombus Undergoing Conventional Transarterial Chemoembolization: An Analysis of 173 Patients
Jing-huan Li et al.
FRONTIERS IN ONCOLOGY (2021)
The Role of Soluble LAG3 and Soluble Immune Checkpoints Profile in Advanced Head and Neck Cancer: A Pilot Study
Andrea Botticelli et al.
JOURNAL OF PERSONALIZED MEDICINE (2021)
Association of TIM-3 with BCLC Stage, Serum PD-L1 Detection, and Response to Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma
Maria Tampaki et al.
CANCERS (2020)
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
Richard S. Finn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Early Change in the Plasma Levels of Circulating Soluble Immune Checkpoint Proteins in Patients with Unresectable Hepatocellular Carcinoma Treated by Lenvatinib or Transcatheter Arterial Chemoembolization
Naoshi Odagiri et al.
CANCERS (2020)
Expression and clinical significance of LAG-3, FGL1, PD-L1 and CD8+T cells in hepatocellular carcinoma using multiplex quantitative analysis
Mengzhou Guo et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2020)
LAG3: a novel immune checkpoint expressed by multiple lymphocyte subsets in diffuse large B-cell lymphoma
Colm Keane et al.
BLOOD ADVANCES (2020)
Expression of lymphocyte-activating gene 3 and T-cell immunoreceptor with immunoglobulin and ITIM domains in cutaneous melanoma and their correlation with programmed cell death 1 expression in tumor-infiltrating lymphocytes
Woo Jin Lee et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2019)
Results of KEYNOTE-240: phase 3 study of pembrolizumab (Pembro) vs best supportive care (BSC) for second line therapy in advanced hepatocellular carcinoma (HCC).
Richard S. Finn et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Hepatocellular Carcinoma
Augusto Villanueva
NEW ENGLAND JOURNAL OF MEDICINE (2019)
LBA38_PRCheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC)
T Yau et al.
ANNALS OF ONCOLOGY (2019)
Complex interaction networks of cytokines after transarterial chemotherapy in patients with hepatocellular carcinoma
Dong Wook Jekarl et al.
PLOS ONE (2019)
Updated use of TACE for hepatocellular carcinoma treatment: How and when to use it based on clinical evidence
Jean-Luc Raoul et al.
CANCER TREATMENT REVIEWS (2019)
Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3
Jun Wang et al.
CELL (2019)
LAG-3 expression on tumor-infiltrating T cells in soft tissue sarcoma correlates with poor survival
Yi Que et al.
CANCER BIOLOGY & MEDICINE (2019)
Dual PD1/LAG3 immune checkpoint blockade limits tumor development in a murine model of chronic lymphocytic leukemia
Marina Wierz et al.
BLOOD (2018)
Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases
Jorge A. Marrero et al.
HEPATOLOGY (2018)
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
Andrew X. Zhu et al.
LANCET ONCOLOGY (2018)
Guidelines for Diagnosis and Treatment of Primary Liver Cancer in China (2017 Edition)
Jian Zhou et al.
LIVER CANCER (2018)
Soluble LAG3 acts as a potential prognostic marker of gastric cancer and its positive correlation with CD8+T cell frequency and secretion of IL-12 and INF-γ in peripheral blood
Na Li et al.
CANCER BIOMARKERS (2018)
sLAG-3 in non-small-cell lung cancer patients' serum
Yayi He et al.
ONCOTARGETS AND THERAPY (2018)
Prognostic Value of Lymphocyte Activation Gene-3 (LAG-3) Expression in Esophageal Squamous Cell Carcinoma
Yu Zhang et al.
JOURNAL OF CANCER (2018)
LAG-3 Protein Expression in Non-Small Cell Lung Cancer and Its Relationship with PD-1/PD-L1 and Tumor-Infiltrating Lymphocytes
Yayi He et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
Anthony B. El-Khoueiry et al.
LANCET (2017)
LAG-3+tumor infiltrating lymphocytes in breast cancer: clinical correlates and association with PD-1/PD-L1+tumors
S. Burugu et al.
ANNALS OF ONCOLOGY (2017)
Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial
Tim Meyer et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2017)
LAG-3 confers poor prognosis and its blockade reshapes antitumor response in head and neck squamous cell carcinoma
Wei-Wei Deng et al.
ONCOIMMUNOLOGY (2016)
EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolisation
Roopinder Gillmore et al.
JOURNAL OF HEPATOLOGY (2011)
LAG-3 regulates CD8+T cell accumulation and effector function in murine self- and tumor-tolerance systems
Joseph F. Grosso et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
A soluble lymphocyte activation gene-3 (sLAG-3) protein as a prognostic factor in human breast cancer expressing estrogen or progesterone receptors
F Triebel et al.
CANCER LETTERS (2006)
Expression of lymphocyte activation gene 3 (LAG-3) on B cells is induced by T cells
M Kisielow et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2005)
Negative regulation of T cell homeostasisby lymphocyte activation gene-3 (CD223)
CJ Workman et al.
JOURNAL OF IMMUNOLOGY (2005)
MHC class II signal transduction in human dendritic cells induced by a natural ligand, the LAG-3 protein (CD223)
S Andreae et al.
BLOOD (2003)
分享论文
